Table 5.

Potency of human soluble CR1 truncation variants containing duplicated LHR-B/C domains in complement pathway-specific Wieslab and red blood cell hemolytic assays

Human CR1 truncation	Wieslab IC50 (nM) ± SD			Hemolytic IC50 (nM) ± SD
Domain	Classical	Lectin	Alternative	Classical	Alternative
LHR-ABC/CSL040	0.8 ± 0.2	0.4 ± 0.04	9.4 ± 1.2	0.2 ± 0.1a	5.0 ± 1.1
LHR-AABC	1.1 ± 0.3	0.7 ± 0.5	9.7 ± 3.1	0.1 ± 0.03	5.9 ± 2.2
LHR-ABCC	0.4 ± 0.2∗	0.1 ± 0.05∗∗	0.9 ± 0.4∗∗∗	0.1 ± 0.03	1.7 ± 0.5∗
LHR-BBCC	1.5 ± 0.5	0.2 ± 0.1	4.7 ± 1.7∗	0.7 ± 0.3∗	5.4 ± 0.3
LHR-BBC	4.4 ± 1.7∗	0.8 ± 0.3	15.5 ± 6.0	1.7 ± 0.5a∗	12.6 ± 0.5∗∗∗

CSL040 containing LHR-ABC was used as a control/comparator. The IC₅₀ values listed are the mean ± SD of three independent experiments. Statistically significant differences for individual HuCR1 fragment IC₅₀ values compared to CSL040 for each pathway assay were calculated by an unpaired t test; ∗ p < 0.05; ∗∗ p < 0.005; ∗∗∗ p < 0.0005.

CR1, complement receptor 1; LHR, long homologous repeat.

^aFrom the same dataset used for Figure 5/Table 4.